LitAlert ~~

    • PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer.
    • Dillon KM, Bekele RT, Sztupinszki Z, Hanlon T, Rafiei S, Szallasi Z, Choudhury AD, Mouw KW.
    • NPJ Precis Oncol. 2022 Jun 29;6(1):49. doi: 10.1038/s41698-022-00291-7.
    • Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer.
    • McClurg DP, Urquhart G, McGoldrick T, Chatterji S, Miedzybrodzka Z, Speirs V, Elsberger B.
    • Cancers (Basel). 2022 Jun 28;14(13):3175. doi: 10.3390/cancers14133175.